Top-News
Werbung
Attraktive Knock-Outs auf Regeneron Pharmaceuticals Inc
Typ Hebel Bid / Ask WKN
Call
4,7 12,76 € / 13,34 €
FC03MF
Typ Hebel Bid / Ask WKN
Put
5,2 11,64 € / 12,22 €
SY4NL1
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Aktie News

Aktie
WKN:  881535 ISIN:  US75886F1075 US-Symbol:  REGN Branche:  Biotechnologie Land:  USA
623,40 €
+2,40 €
+0,39%
12:25:27 Uhr
Depot/Watchlist
Marktkapitalisierung *
64,49 Mrd. €
Streubesitz
7,22%
KGV
18,37
Dividende
0,88 $
Dividendenrendite
0,12%
neu: Nachhaltigkeits-Score
62 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,14: MM7U27
Werbung

Regeneron Pharmaceuticals News

04.02.25 - wallstreetONLINE Redaktion
Nach monatelanger Talfahrt: Bayer-Partner Regeneron: Ist das das Ende?
Monatelang kannte die Aktie von US-​Biotechunternehmen Regeneron nur eine Richtung – nach unten. Am Dienstag beweisen die Käuferinnen und Käufer jedoch Mut.Um fast 50 ...
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN PR Newswire
04.02.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.02.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
03.02.25 - PR Newswire
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN PR Newswire
31.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
31.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
31.01.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN PR Newswire
30.01.25 - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PR Newswire
30.01.25 - PR Newswire
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PR Newswire
29.01.25 - PR Newswire
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit PR Newswire
28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming ...
28.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PR Newswire
27.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
27.01.25 - PR Newswire
Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) PR Newswire
24.01.25 - wallstreetONLINE Redaktion
Renditejäger aufgepasst: Die vielversprechendsten Dividendenaktien von morgen!
Ein starker Arbeits­markt und höhere Staatsanleiherenditen belasten derzeit die Performance von Dividendenaktien. Alternativen sind gefragt.Chris Senyek, Chief Investment ...
24.01.25 - PR Newswire
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PR Newswire
23.01.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PR Newswire
23.01.25 - PR Newswire
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search PR Newswire
23.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »